Value of albumin-bilirubin score in predicting the prognosis of cirrhotic patients with esophagogastric variceal bleeding

Mengyuan SUN; Xiaoxing XIANG

doi:10.3969/j.issn.1001-5256.2021.03.017

Volume 37 Issue 3

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(3): 590-594

PDF( 2118 KB)

Value of albumin-bilirubin score in predicting the prognosis of cirrhotic patients with esophagogastric variceal bleeding

DOI: 10.3969/j.issn.1001-5256.2021.03.017

Mengyuan SUN¹,
Xiaoxing XIANG^{2
,
,}

1.
Yangzhou University Medical College, Yangzhou, Jiangsu 225009, China
2.
Department of Gastroenterology, School of Clinical Medicine, Yangzhou University, Yangzhou, Jiangsu 225001, China

Received Date: 2020-09-06
Accepted Date: 2020-10-10
Published Date: 2021-03-20

Abstract

Abstract

Objective To investigate the value of albumin-bilirubin (ALBI) score in predicting the prognosis of cirrhotic patients with esophagogastric variceal bleeding, and to identify risk stratification and increase clinical applicability. Methods A retrospective analysis was performed for the clinical data of 273 cirrhotic patients with esophagogastric variceal bleeding who were hospitalized in Subei People's Hospital of Jiangsu from October 2012 to August 2018, and all patients received standard management after admission. Survival status was obtained through electronic medical records and telephone follow-up, and according to the prognosis in August 2020, the patients were divided into death group with 109 patients and survival group with 164 patients. General data were compared between the two groups. The Mann-Whitney U test was used for comparison of continuous variables between two groups, and the chi-square test or the Fisher's exact test was used for comparison of categorical variables between two groups; univariate and multivariate Cox regression analyses were used to identify independent risk factors for prognosis. The Kaplan-Meier curve was used to analyze the survival rates of patients with different ALBI grades, and the log-rank test was used for comparison between groups; the receiver operating characteristic (ROC) curve was plotted to compare the ability of ALBI score, Child-Turcotte-Pugh (CTP) score, and Model for End-Stage Liver Disease (MELD) score in predicting short-term (6 weeks) and long-term prognoses. Results During follow-up, 109 patients (39.9%) died, and the death group had a significantly higher ALBI score than the survival group [-1.49 (-1.82 to-1.11) vs-1.79 (-2.22 to-1.49), Z=5.630, P < 0.001]. The univariate analysis showed that age ≥55 years, hemoglobin ≤100 g/L, neutrophil count ≥3.4×10⁹/L, platelet count ≤42×10⁹/L, albumin ≤28 g/L, total bilirubin ≥21 μmol/L, alanine aminotransferase ≥42 U/L or aspartate aminotransferase ≥48 U/L, creatinine ≥94 μmol/L, serum sodium ≤137 mmol/L, international normalized ratio of prothrombin ≥1.5, ascites, and hepatic encephalopathy were risk factors for death in cirrhotic patients with esophagogastric variceal bleeding, and the patients with ALBI grade 3 had a significantly higher risk of death than those with ALBI grade 1 or 2; prophylactic ligation was a protective factor for survival improvement in cirrhotic patients with esophagogastric variceal bleeding (all P < 0.05). The multivariate analysis showed that age ≥55 years (hazard ratio [HR]=2.531, 95% confidence interval [CI]: 1.624-3.946, P < 0.001), creatinine ≥94 μmol/L (HR=1.935, 95% CI: 1.208-3.100, P=0.006), serum sodium ≤137 mmol/L [HR=1.519, 95% CI: 1.015-2.274, P=0.042], ascites (HR=1.641, 95% CI: 1.041-2.585, P=0.033), hepatic encephalopathy (HR=9.972, 95% CI: 3.961-25.106, P < 0.001), and ALBI grade 3 (HR=1.591, 95% CI: 1.007-2.515, P=0.047) were independent risk factors for death. The patients with ALBI grade 3 had a significantly lower survival rate than those with ALBI grade 1 (χ²=18.691, P < 0.001) and ALBI grade 2 (χ²=21.364, P < 0.001), and the patients with ALBI grade 1 had a significantly higher survival rate than those with ALBI grade 2 (χ²=6.513, P=0.011). The ROC curve analysis showed that ALBI score, CTP score, and MELD score had an area under the ROC curve (AUC) of 0.770, 0.730, and 0.706, respectively, in predicting short-term (6 weeks) prognosis, and they had an AUC of 0.701, 0.685, and 0.659, respectively, in predicting long-term prognosis. Conclusion ALBI score has a good value in predicting short-term (6 weeks) and long-term prognoses of cirrhotic patients with esophagogastric variceal bleeding, and the risk of death increases with ALBI grade. ALBI score can be used as an objective and simple model in clinical practice.
- Albumin-Bilirubin Score,
- Liver Cirrhosis,
- Esophageal and Gastric Varices,
- Prognosis

FullText(HTML)

References(16)

References

[1]	KOVACS T, JENSEN DM. Varices: Esophageal, gastric, and rectal[J]. Clin Liver Dis, 2019, 23(4): 625-642. DOI: 10.1016/j.cld.2019.07.005
[2]	MANDAL AK, PAUDEL MS, KC S, et al. Factors predicting mortality of acute variceal bleeding in liver cirrhosis[J]. JNMA J Nepal Med Assoc, 2018, 56(209): 493-496. DOI: 10.31729/jnma.3408
[3]	FORTUNE BE, GARCIA-TSAO G, CIARLEGLIO M, et al. Child-Turcotte-Pugh class is best at stratifying risk in variceal hemorrhage: Analysis of a US multicenter prospective study[J]. J Clin Gastroenterol, 2017, 51(5): 446-453. DOI: 10.1097/MCG.0000000000000733
[4]	WANG J, ZHANG Z, YAN X, et al. Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis[J]. Dig Liver Dis, 2019, 51(8): 1172-1178. DOI: 10.1016/j.dld.2019.01.011
[5]	HSIEH YC, LEE KC, WANG YW, et al. Correlation and prognostic accuracy between noninvasive liver fibrosis markers and portal pressure in cirrhosis: Role of ALBI score[J]. PLoS One, 2018, 13(12): e0208903. DOI: 10.1371/journal.pone.0208903
[6]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention andtreatment for chronic hepatitis B: A 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2015.12.002 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002
[7]	XU XY, DING HG, JIA JD, et al. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2016.02.002 徐小元, 丁惠国, 贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002
[8]	JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6): 550-558. DOI: 10.1200/JCO.2014.57.9151
[9]	de FRANCHIS R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022
[10]	TANTAI XX, LIU N, YANG LB, et al. Prognostic value of risk scoring systems for cirrhotic patients with variceal bleeding[J]. World J Gastroenterol, 2019, 25(45): 6668-6680. DOI: 10.3748/wjg.v25.i45.6668
[11]	WU SL, ZHENG YX, TIAN ZW, et al. Scoring systems for prediction of mortality in decompensated liver cirrhosis: A meta-analysis of test accuracy[J]. World J Clin Cases, 2018, 6(15): 995-1006. DOI: 10.12998/wjcc.v6.i15.995
[12]	FUJITA K, NOMURA T, MORISHITA A, et al. Prediction of transplant-free survival through albumin-bilirubin score in primary biliary cholangitis[J]. J Clin Med, 2019, 8(8): 1258. DOI: 10.3390/jcm8081258
[13]	Chinese Society of Hepatogy, Chinese MedicalAssociation. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.11.006 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006
[14]	PUENTE A, HERNÁNDEZ-GEA V, GRAUPERA I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: An updated systematic review[J]. Liver Int, 2014, 34(6): 823-833. DOI: 10.1111/liv.12452
[15]	BRUNNER F, BERZIGOTTI A, BOSCH J. Prevention and treatment of variceal haemorrhage in 2017[J]. Liver Int, 2017, 37(Suppl 1): 104-115. http://www.ncbi.nlm.nih.gov/pubmed/28052623
[16]	Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension (2019 edition)[J]. Chin J Dig Surg, 2019, 18(12): 1087-1093. (in Chinese) 中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中华消化外科杂志, 2019, 18(12): 1087-1093.

Relative Articles

[1]	Yangqing MA, Haina FAN, Xin SUN, Chenghai LIU. Role of Golgi protein 73(GP73) in diagnosis of chronic liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(8): 1999-2004. doi: 10.3969/j.issn.1001-5256.2023.08.035
[2]	Hang ZHANG, Jinchun LIU. Role of serum Golgi protein 73 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(3): 657-662. doi: 10.3969/j.issn.1001-5256.2023.03.028
[3]	Peiling YE, Hongyun JIA, Liang PENG. Mechanism of action of GP73 in the regulation of liver cancer: An analysis based on transcriptome sequencing[J]. Journal of Clinical Hepatology, 2021, 37(8): 1861-1866. doi: 10.3969/j.issn.1001-5256.2021.08.022
[4]	Luo WenPing, Ma Hong, Wang Yu. Advances in the application of transient elastography in noninvasive diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(3): 635-639. doi: 10.3969/j.issn.1001-5256.2019.03.041
[5]	Zheng ShaoQiu, Wang QiZhi. Current status and prospects of research on noninvasive diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(1): 197-200. doi: 10.3969/j.issn.1001-5256.2019.01.043
[6]	Zhang LiJun, Liu MingJun, Wang Shuai, Wang Lin, Wang RuKun, Hou HuaBin, Sun GuiRong, Zhang NaNa, Liu LinJie. Clinical value of Golgi protein 73 and hyaluronic acid in diagnosis of the progression of hepatitis B virus-related chronic liver diseases[J]. Journal of Clinical Hepatology, 2018, 34(1): 63-67. doi: 10.3969/j.issn.1001-5256.2018.01.013
[7]	Yao MingJie, Wang LeiJie, Guan GuiWen, Xi JingYuan, Liu ShuHong, Wen XiaJie, Zou Jun, Chen XiangMei, Jia JiDong, Zhao JingMin, Lu FengMin. Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(4): 755-759. doi: 10.3969/j.issn.1001-5256.2018.04.012
[8]	Zhao YunSheng, Zhang LiNa, Huo LiJing, Pei Liu, Li QiuPing, Li HongChen, Jin Liang. Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(8): 1707-1711. doi: 10.3969/j.issn.1001-5256.2018.08.023
[9]	Lu FengMin. Serological diagnosis of hepatocellular carcinoma:challenges and opportunities[J]. Journal of Clinical Hepatology, 2017, 33(7): 1262-1265. doi: 10.3969/j.issn.1001-5256.2017.07.011
[10]	Yang ErNa, Cao WuKui. Research advances in noninvasive diagnosis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2209-2213. doi: 10.3969/j.issn.1001-5256.2017.11.035
[11]	Wei FengXian, Liu Zhao, Geng Jie, Su GuoHong, Chen Mo, Wang ManCai, Cao WeiJia, Zhang YouCheng. Research advances in association between Golgi protein 73 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(8): 1595-1598. doi: 10.3969/j.issn.1001-5256.2017.08.040
[12]	Yang YiLiang, Cui YuanYuan, Hu Yue, Xu HongQin, Pan Yu. Role of the Mac-2 binding protein glycosylation isomer in diagnosis of chronic liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(12): 2395-2398. doi: 10.3969/j.issn.1001-5256.2016.12.036
[13]	Yang MingLei, Yao DingKang. Application of magnetic resonance elastography as a non-invasive technique for diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(3): 588-592. doi: 10.3969/j.issn.1001-5256.2016.03.042
[14]	Zhao Wei. Clinical significance of plasma and urine neutrophil gelatinase-associated lipocalin levels in diagnosis of acute kindney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1874-1877. doi: 10.3969/j.issn.1001-5256.2015.11.025
[15]	Wu Qiong, Xu GuangHua. Recent research findings on non-invasive diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 295-299. doi: 10.3969/j.issn.1001-5256.2015.02.040
[16]	Liu XiuHong, Zhao YiMing, Li Ning, Jin BoXun, Yan HuiPing, Zhao YuanShun, Li Ang, Han Zhen, Zhang AiYing. Diagnostic values of plasma Golgi protein-73 and platelet count for different stages of HBV-related liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(9): 1469-1472. doi: 10.3969/j.issn.1001-5256.2015.09.025
[17]	Zhang Qin, Dan HongLi, Xu Wei. Value of serum GP73,AFP,and AFP-L3 in diagnosis of liver cancer and recurrence monitoring after radiofrequency ablation[J]. Journal of Clinical Hepatology, 2015, 31(2): 232-235. doi: 10.3969/j.issn.1001-5256.2015.02.021
[18]	Cai JunJun, Han Tao. Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1352-1356. doi: 10.3969/j.issn.1001-5256.2014.12.030
[19]	Gao HaiFeng. Value of combined detection of serum AFP and GP73 in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(7): 660-662. doi: 10.3969/j.issn.1001-5256.2014.07.022
[20]	Zhu Chen, Sun YuanYuan, Jin Yan. Values of serum AFP, GGTⅡ and GP73 in diagnosis of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1064-1066. doi: 10.3969/j.issn.1001-5256.2014.10.022

Supplements(0)

Cited By

Cited by

Periodical cited type(17)

1.	郭堑，农村立，韦秋芳. 慢性乙型肝炎肝纤维化患者血清Copeptin和PCT表达水平及其临床价值研究. 现代检验医学杂志. 2023(02): 112-117+189 .
2.	李初谊，王俊科，李斌，温雪，魏晓静，于晓辉. 血浆置换对慢加急性肝衰竭辅助治疗的效果评价. 海南医学院学报. 2022(16): 1228-1231 .
3.	王鑫，张国民，牛兴杰，李萍，张冰. 外周血CD14~+CD16~+单核细胞亚群在肝衰竭继发感染患者中的检测价值. 中国免疫学杂志. 2020(09): 1124-1127+1130 .
4.	姜曼蕾，许飞，胡江玲，罗嘉裕，罗方云. IL-6、CRP、PCT和内毒素预判肝衰竭合并细菌感染风险中的临床价值. 中华医院感染学杂志. 2020(20): 3062-3065 .
5.	张国民，王鑫，韩智炜，牛兴杰，刘志慧，崔凤梅. 降钙素原、白细胞介素6、sCD14、CD64检测在肝功能衰竭患者诊治中的临床研究. 中国现代医学杂志. 2019(03): 47-51 .
6.	江艳霞，骆小燕，骆旭航，龚安安，孙爱华. 血清降钙素原在胆管炎危重度早期评估中的价值研究. 中国卫生检验杂志. 2019(04): 462-463+468 .
7.	张国民，韩智炜，牛兴杰，刘志慧，王鑫. IL-6、CD14、CD64检测在感染所致肝衰竭患者中意义. 现代医学. 2019(02): 137-140 .
8.	黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 .
9.	杨丽霞，张伦理，赖玲玲，方铭. 腹水中肝素结合蛋白及降钙素原对肝硬化腹水伴自发性细菌性腹膜炎的诊断价值. 临床肝胆病杂志. 2019(06): 1266-1269 . 本站查看
10.	李薇，任小丹，何谦，周荣幸. 血清降钙素原检测对胆道梗阻合并感染者的预测价值. 中华实验和临床感染病杂志(电子版). 2019(03): 245-249 .
11.	张国民，韩智炜，牛兴杰，刘志慧，崔凤梅，王鑫. PCT、IL-6、CD14、CD64及TNF-α表达对肝衰竭合并医院感染患者预后的影响. 中华医院感染学杂志. 2019(16): 2450-2453 .
12.	王鑫，张国民，牛兴杰，李萍，张冰. 肝衰竭继发感染患者外周血Toll样受体4及降钙素原、C反应蛋白变化情况分析. 现代消化及介入诊疗. 2019(10): 1084-1087+1094 .
13.	石春霞，陈倩，王瑶，焦方舟，龚作炯. 肝功能衰竭并感染患者血清正五聚蛋白3和肝素结合蛋白及降钙素原水平变化. 中华实用诊断与治疗杂志. 2019(12): 1188-1190 .
14.	顾静，王艳，陈丽，徐英，甘建和. HBV相关慢加急性肝衰竭患者血清IL-32和IL-10水平变化及意义. 临床肝胆病杂志. 2018(04): 801-805 . 本站查看
15.	王小芳，奉万盛，周红翠，邱咏佳. 血清降钙素原、白细胞计数、C-反应蛋白与细菌血培养联合检测在感染患者中的应用价值. 中国医药导报. 2018(19): 75-78 .
16.	沈素晶，邓超，李霭文，谭俊青. 不同化学发光检测系统测定PCT结果的相关性分析. 实验与检验医学. 2018(06): 873-875+891 .
17.	詹金美，林欢，孙家敏. 定量检测血清降钙素原在诊断肝衰竭患者腹腔感染细菌类型中的价值. 中外医疗. 2017(28): 34-36 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (910) PDF downloads(100)

Value of albumin-bilirubin score in predicting the prognosis of cirrhotic patients with esophagogastric variceal bleeding

DOI: 10.3969/j.issn.1001-5256.2021.03.017